Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 12/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900658 | 1.00 | CETP (0.39) | CETPBACE1SCN9AEPHX2LMNA | |
| SCHEMBL5754542 | 1.00 | CETP (0.39) | CETPBACE1SCN9AEPHX2LMNA | |
| SCHEMBL5749779 | 0.96 | CETP (0.40) | CETPBACE1SCN9AEPHX2LMNA | |
| SCHEMBL5752918 | 0.93 | MAPK14 (0.42) | CETP | |
| SCHEMBL5755540 | 0.93 | MAPK14 (0.41) | CETPBACE1SCN9A | |
| SCHEMBL5752003 | 0.92 | CETP (0.42) | CETPBACE1SCN9AMAPT | |
| SCHEMBL5749902 | 0.90 | CNR1 (0.38) | SCN9AMAPT | |
| SCHEMBL5752979 | 0.90 | ADRB1 (0.38) | CETPSCN9A | |
| SCHEMBL5749925 | 0.89 | CETP (0.35) | CETPBACE1SCN9A | |
| SCHEMBL5751303 | 0.89 | BACE1 (0.34) | CETPBACE1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | claimed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | claimed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | claimed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7897175-B2 | Cholesteryl ester transfer protein (CETP) such as torcetrapib; 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase); two drugs are separate from each other; improved chemical stability of the HMG-CoA reductase inhibitor | BEND RESEARCH, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1961419-B1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER PROD INC (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1961419-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | Pfizer Products Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| WO-2004056395-A1 | COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056358-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056359-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056396-A1 | DOSAGE FORMS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS WITH IMPROVED PERFORMANCE | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | CETP 1/4885BACE1 835/4885SCN9A 3335/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885BACE1 675/4885SCN9A 4236/4885 |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | CETP, HMGCR, MTTP | CETP 1/4885BACE1 1994/4885SCN9A 3280/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885BACE1 675/4885SCN9A 4236/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885BACE1 1136/4885SCN9A 1846/4885 |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | CETP, HMGCR, CHLSN | CETP 1/4885BACE1 1758/4885SCN9A 4040/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885BACE1 675/4885SCN9A 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.